Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Call for input regarding electric field therapy (Optune) for the New Methods framework

21 Sep 2022

In 2013, Norway established a framework, "New Methods," for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment. In this framework, all innovations should undergo HTA before being funded.

In September 2022, Ordering Forum for New Methods has invited interested parties regarding electric field therapy (Optune, Tumor Treating Fields) alone or in combination with drugs for certain groups of glioblastoma patients, based on genome sequencing and biomarkers (indication II).

The technology was previously evaluated within New Methods in combination with temozolomide for the treatment of glioblastoma; the Decision of 2020 can be seen here.

Information shall be submitted before November 8, 2022. Ordering Forum will be held on November 21, 2022, and will decide whether the method will undergo evaluation at the national level.

See more details in Norwegian here and here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).